Executive record

Alvin Shih

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:alvin-shihVersion: public-0As of: 2026-09-28

Not yet claimed6 published Claims1 sources

Key Claims

Biography

Chief executive officer of Imbria Pharmaceuticals developing therapeutics for rare and common cardiac diseases. Broad experience in drug development with focus on rare diseases, including as COO of Pfizer's rare disease research unit from 2010-2014.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedOACC 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. OACC 10-K executive officers

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Oaktree Acquisition Corp. III Life Sciences · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Alvin Shih is also linked to Imbria Pharmaceuticals; Tenza; Zevra Therapeutics, Inc. as Chief Executive Officer; Director. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026